Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas

With all the fretting from the pharmaceutical industry about competition from China, patent protection losses, price reduction initiatives and other government measures with the potential to hit pr | In the second quarter, nine of the world's top 25 drugmakers accomplished double-digit revenue increases, led again by Eli Lilly, which charted a 48% sales gain. The revenue boom was even more pronounced when comparing figures between the first and second quarters. Of the top 25 drugmakers, more than half realized double-digit sequential gains and only one saw a decline.